A CHINESE SUBGROUP ANALYSIS OF THE ASIAN PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VONOPRAZAN 10 OR 20 MG COMPARED WITH LANSOPRAZOLE 15 MG IN THE MAINTENANCE TREATMENT OF ASIAN PATIENTS WITH EROSIVE ESOPHAGITIS

YU HUI  ¹     Jiaming Qian  ²     Shutian Zhang  ³     Ning Dai  ⁴     Nobuo Funao  ⁵     yuuichi sakurai  ⁵     lu dong  ⁶     Li Xie  ⁶     Minhu Chen  ^7    
1 The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
² Peking Union Medical College Hospital, Beijing, China
³ Beijing Friendship Hospital, Capital Medical University, Beijing, China
⁴ Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, China
⁵ Takeda Pharmaceutical Company, Osaka, Japan
⁶ Takeda Pharmaceutical Company, Beijing, China
⁷ The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China

Session
Oesophageal, gastric and duodenal disorders (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)